Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The pancreas is an organ located in the abdomen that secretes several hormones in the body, including insulin and glucagon, as well as digestive enzymes. Furthermore, insulin helps cells in the body to take up glucose (sugar) from the blood to use for energy, which lowers blood glucose levels. Glucagon causes the liver to release stored glucose, which raises blood glucose levels. Moreover, Type 1 diabetes is characterized by deficient insulin production and requires daily administration of insulin and type 2 diabetes occurs when the pancreas does not produce enough insulin or the body becomes resistant to the insulin. The artificial pancreas devices are used in the treatment of Type 1 Diabetes. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Additionally, this device system stimulates the glucose regulating function of a healthy pancreas and are also referred to as closed-loop system or autonomous system for glycemic control or bionic pancreas. Furthermore, according to the W.H.O, in 2014, 8.5% of adults aged 18 years and older had diabetes. Likewise, in 2016, diabetes was the direct cause of 1.6 million deaths and in 2012, high blood glucose was the cause of another 2.2 million deaths globally. Hence, owing to the high prevalence rate of diabetes around the world is expected to fuel the artificial pancreas devices market in near future.
The artificial pancreas devices market is segmented by device type, end user and geography.
The various device types of the artificial pancreas devices market are covered in the report such as threshold suspend device system, control-to-range (CTR) systems and control-to-target (CTT) systems. Among these, the control-to-target (CTT) systems dominated the artificial pancreas devices market in 2018, this system sets target glucose levels and tries to maintain these levels at all times. This system is fully automated and requires no interaction from the user. There are two subtypes of CTT systems currently being investigated i.e. insulin-only and bi-hormonal and a hybrid system option that can be used in either of the system types.
Based on end user, the artificial pancreas devices market is segmented into hospitals and medical centres. The hospitals segment dominated the market in 2018, because hospitals are highly preferred by patients over other healthcare centers since they provide treatment, diagnosis, and surgical intervention for various disorders.
The artificial pancreas devices market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. The North America region dominated the artificial pancreas devices market in 2018, owing to high number of diabetic patients in this region. Thus, the sales of insulin delivery devices are high in the region. In 2015, 9.4% American population had diabetes. Moreover, the prevalence of diabetes in Americans age 65 and older remains high at 25.2%. Whereas, Asia Pacific is expected to witness the fastest growth rate during the forecast period.
The market involves various key companies in the global artificial pancreas devices market such as Medtronic Plc, Johnson & Johnson, Insulet Corp, Tandem Diabetes Care, F. Hoffmann-La Roche Ltd, Beta Bionics, Bigfoot Biomedical, Inc., Inreda Diabetic B.V., Dexcom, Inc. and Cellnovo. The majority of companies are aiming towards product launches and mergers & acquisitions to enhance their visibility in the high competitive arena of the surgical lasers market.
December 2016, OneTouch Vibe plus Insulin Pump by Animas received FDA approval and Health Canada License for the sale of the product. This system will enable patients to see their glucose reading at all times either on their pump or using the Dexcom G5 App on their smart phone, and to deliver the precise amounts of insulin they may need from the pump.
January 2016, Animas received FDA approval for Animas Vibe Insulin Pump, the device to manage of diabetes in children and adolescents. The Animas Vibe System allows patients and their caregivers to view glucose data and administer insulin right from the pump, making it easy to fine-tune insulin delivery to help manage their diabetes.
June 2016, Tandem Diabetes Care cleared its FDA approval for remote software update tool for insulin pump. This represents the first time an insulin pump manufacturer has provided a software update for customers using their personal computer.
September 2016, the Tandem Diabetes Care received FDA approval for their product t:slim G4 Insulin Pump. The t:slim G4 Pump is the only pump that conveniently displays CGM graphs and trend information with current insulin delivery activity together on the home screen to help make informed treatment decisions.
September 28, 2016, the FDA approved the first hybrid closed loop system, the Medtronic's MiniMed 670G System , intended to automatically monitor blood sugar and adjust basal insulin doses in people with type 1 diabetes.
The artificial pancreas devices market is segmented by device type, end user and geography. The various device types of the artificial pancreas devices market are covered in the report such as threshold suspend device system, control-to-range (CTR) systems and control-to-target (CTT) systems. Among these, the control-to-target (CTT) systems dominated the artificial pancreas devices market in 2018, this system sets target glucose levels and tries to maintain these levels at all times. This system is fully automated and requires no interaction from the user.
Based on end user, the artificial pancreas devices market is segmented into hospitals and medical centres. The hospitals segment dominated the market in 2018, because hospitals are highly preferred by patients over other healthcare centers since they provide treatment, diagnosis, and surgical intervention for various disorders.
The artificial pancreas devices market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. The North America region dominated the artificial pancreas devices market in 2018, owing to high number of diabetic patients in this region. Thus, the sales of insulin delivery devices are high in the region.
Why to buy this report:
